Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | RECQL | P46063 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9381614 | 0.87 | RAB9A (0.65) | SMN1; SMN2LMNATP53TSHRPKM | |
| Water SCHEMBL9387383 | 0.86 | RAB9A (0.64) | SMN1; SMN2LMNATP53TSHRPKM | |
| SCHEMBL5706320 | 0.81 | SYK (0.53) | SMN1; SMN2LMNATP53TSHRPKM | |
| SCHEMBL3525964 | 0.81 | PKM (0.50) | SMN1; SMN2LMNATP53TSHRPKM | |
| SCHEMBL10045058 | 0.81 | CYP1A2 (0.67) | SMN1; SMN2TSHRPKMRAB9ANPC1 | |
| SCHEMBL5762561 | 0.80 | PLA2G7 (0.58) | SMN1; SMN2LMNATP53TSHRPKM | |
| SCHEMBL27791948 | 0.79 | NPC1 (0.50) | SMN1; SMN2LMNATP53TSHRPKM | |
| SCHEMBL27431502 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNATP53TSHRPKM | |
| SCHEMBL15508074 | 0.78 | PKM (1.00) | SMN1; SMN2LMNATSHRPKMGAA | |
| SCHEMBL28717675 | 0.78 | CYP1A2 (0.77) | SMN1; SMN2RAB9ANPC1PTGS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112390755-B | Heteroaryl method for amine | 中国科学院理化技术研究所 | 2024-08-02 | — | — | CN | claimed |
| EP-3812040-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2023-01-11 | — | — | EP | disclosed |
| EP-3812040-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2023-01-11 | — | — | EP | disclosed |
| CN-110201721-B | Complex compounds | 庄信万丰股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3812040-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-3812040-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-3154689-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2021-01-27 | — | — | EP | disclosed |
| CN-106661071-B | Complex compounds | 庄信万丰股份有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-9777030-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-03 | — | — | US | disclosed |
| US-9777030-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-03 | — | — | US | disclosed |
| WO-2012040754-A2 | NOVEL THIAZOLAMINE DERIVATES AS DIFFERENTIATION ACCELERATORS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040754-A2 | NOVEL THIAZOLAMINE DERIVATES AS DIFFERENTIATION ACCELERATORS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2012-04-05 | — | — | WO | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | SMN1; SMN2 4364/4885LMNA 2263/4885TP53 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.